Henry Schein, Inc. (NASDAQ:HSIC) Receives $92.27 Consensus PT from Brokerages

Henry Schein, Inc. (NASDAQ:HSIC) has been assigned an average rating of “Hold” from the fifteen research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $92.2667.

Several brokerages recently commented on HSIC. Barrington Research set a $104.00 price objective on shares of Henry Schein in a research report on Wednesday, August 5th. Citigroup reaffirmed a “buy” rating and issued a $112.00 target price (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. UBS Group set a $94.00 target price on shares of Henry Schein and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. BTIG Research reiterated a “buy” rating and set a $100.00 price target on shares of Henry Schein in a report on Wednesday, August 5th. Finally, Mizuho reduced their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th.

Institutional Trading of Henry Schein

A number of institutional investors and hedge funds have recently modified their holdings of HSIC. Ameriprise Financial Inc. grew its holdings in shares of Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after acquiring an additional 2,199,695 shares during the period. Bank of Montreal Can lifted its holdings in Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after acquiring an additional 2,087,666 shares during the period. Norges Bank bought a new position in Henry Schein in the fourth quarter valued at about $88,116,000. Southpoint Capital Advisors LP boosted its position in Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after purchasing an additional 700,000 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after purchasing an additional 668,182 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Up 1.2%

Shares of NASDAQ:HSIC opened at $89.18 on Friday. The stock has a fifty day simple moving average of $83.98 and a two-hundred day simple moving average of $78.81. The stock has a market capitalization of $9.94 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 1.68 and a beta of 0.80. Henry Schein has a 12-month low of $61.94 and a 12-month high of $92.18. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 4th. The company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The business had revenue of $3.46 billion for the quarter, compared to the consensus estimate of $3.37 billion. During the same period in the previous year, the company posted $1.10 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, research analysts anticipate that Henry Schein will post 5.35 earnings per share for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.